Project Grant R01HL171598
Award Date
8/26/24
Completion Date
5/31/28
Dollars Obligated
$759K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Chapel Hill, NC 27599, USA
Similar Awards
This Project Grant award of $495,159 from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research to investigate the role of the CARMIL1 protein in regulating pulmonary endothelial cell barrier function. The research aims to characterize how CARMIL1 influences peripheral actin structure and dynamics, and determine the effect of CARMIL1 expression on endothelial barrier integrity. This work will provide insights into...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $1,659,996.00 to the University of Southern California to conduct research on the role of the PDLIM2 protein in alveolar macrophages and its impact on lung innate immunity, inflammation, and diseases. The research aims to determine the mechanisms by which PDLIM2 regulates alveolar macrophage function, including phagocytosis,...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), will support research focused on understanding the mechanisms underlying neutrophil function and the lung microenvironment during Streptococcus pneumoniae pneumonia and acute lung injury. The $759,983 award to the University of North Carolina at Chapel Hill will fund two main research aims: 1) Determining the changes in neutrophil...
The National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), awarded a $880,735 Project Grant to the University of Washington. The grant, effective February 1, 2025 through November 30, 2028, supports research to investigate the mechanisms by which cell lysis and the release of leukotriene C4 (LTC4) and its metabolite LTD4 activate group 2 innate lymphoid cells (ILC2s) and induce type 2 immunity in the lung. The research aims to...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health (NIH), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $1,061,189 to support research on immune crosstalk in lung injury and fibrosis. The key objectives are: 1) studying epithelial HB-EGF regulation of fibrosis and its interaction with myeloid cells, 2) uncovering mechanisms for impaired innate immunity against gram-positive infections...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $557,649 project grant (CFDA 93.837 - Cardiovascular Diseases Research) to the University of Nevada, Reno (UNR) to study the molecular regulation of beta-2 integrin activation in neutrophil adhesion and inflammation related to cardiovascular disease. The 5-year research project aims to investigate how the proteins kindlin-3 and talin-1 induce activation of beta-2 integrins, which is a key step in neutrophil recruitment and...
The National Institutes of Health National Heart Lung and Blood Institute awarded a $511,680 Project Grant to the University of Illinois under the Cardiovascular Diseases Research program (CFDA 93.837). The grant will fund research from February 2021 through August 2021 to investigate mechanisms by which vascular endothelial cells instruct macrophage fate in inflammatory injury. Specifically, the research will examine how endothelial cell Wnt signaling licenses the differentiation of monocytes...
The federal Project Grant award of $767,077 from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) is supporting research to validate and extend a platform technology for the delivery of protein-based drugs, with a focus on thrombolytic enzymes. The key objectives of the project are to: (I) accommodate an array of thrombolytic proteins, (II) explore multi-drug synergism for thrombolysis, (III) develop photon-responsive drug...
This federal Project Grant award, with ID R01HL177904, was provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research (CFDA 93.837) program. The primary awardee, The Washington University, will receive $773,446 to conduct research focused on understanding early matricellular events in the injured lung and identifying mechanisms critical for stabilizing the provisional matrix. The project aims to determine how platelet/megakaryocyte-derived...
This federal Project Grant award, provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), supports research to investigate the role of perivascular macrophages in promoting endothelial cell regeneration and vascular repair following acute lung injury (ALI) and acute respiratory distress syndrome (ARDS). The $1,875,540 award, with a period of performance from June 15, 2024 to March 31, 2029, will enable researchers at the...